HeyJaredMatthew Shinkle
- Indexed articles, last 90 days
- 22
- Latest publication
- Sep 25, 2026
- Outlet visibility, for Healio
- Top 500K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Nearly a quarter of adults treated for HCV lack follow-up RNA testing (opens the original)
Read excerpt
Approximately one in four adults with hepatitis C virus infection who initiated treatment with direct-acting antivirals did not undergo follow-up RNA testing, according to a research letter published in JAMA Network Open. However, 90% of that unmonitored population had been prescribed at least 56 days of DAA therapy, potentially leaving cured individuals unaccounted for and highlighting a notable gap in HCV surveillance efforts. âMeasuring care outcomes is essential to monitoring progress towa
FDA approves Welireg plus Lenvima for advanced renal cell carcinoma after PD-1/PD-L1 (opens the original)
Read excerpt
The FDA approved belzutifan in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component following treatment with a PD-1 or PD-L1 inhibitor. The combination of belzutifan (Welireg, Merck) plus lenvatinib (Lenvima, Eisai) is indicated for adults with locally advanced or metastatic ccRCC that progressed during or after PD-1/PD-L1 inhibitor therapy, or within 6 months of completing adjuvant PD-1 therapy. The FDA based its decision on findings from the ran
Lyrfigtu gains FDA approval for previously treated cholangiocarcinoma with FGFR2 mutation (opens the original)
Read excerpt
The FDA approved lirafugratinib â a kinase inhibitor â for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma. The indication for lirafugratinib (Lyrfigtu, Elevar Therapeutics) applies to patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. The FDA based its decision on results from the phase 1/2 REFOCUS trial, which enrolled 116 patients with unresectable or metastatic cholangiocarcinoma who had received
Street-based HCV program drives treatment completion, cure for unsheltered homeless adults (opens the original)
Read excerpt
A street-based treatment program could be an effective and supportive way to provide hepatitis C virus care to adults experiencing unsheltered homelessness, results of a qualitative study showed. Findings, published in JAMA Network Open, showed the majority of participants completed treatment and achieved sustained virologic response. Many also reported various psychosocial benefits as a result of engaging in treatment. âThese findings suggest that similar street-based approaches may be valuab
âTake noticeâ: Unexplained GI symptoms after tick bite may signal alpha-gal syndrome (opens the original)
Read excerpt
Summer may be winding down, but tick season is still in full swing â and that means the possibility of developing alpha-gal syndrome remains high in certain areas of the country. The food allergy â caused by an immunoglobulin E (IgE)-mediated reaction hours after eating beef, pork or other mammalian meat or mammalian-derived products and triggered by the bite of a lone star tick â should be considered among patients with unexplained gastrointestinal symptoms like abdominal pain, vomiting a
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Healio, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.